- NCIt
- C6959
Loading cancer entity…
Loading cancer entity…
Clinical trials
38 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02026271 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | completed | Phase 1 | 40 | Alaunos TherapeuticsINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT01922076 |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas |
| completed |
| Phase 1 |
| 46 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Jan 31, 2024 |
| clinicaltrials |
| NCT03072134 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT00303849 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | completed | Phase 1 / Phase 2 | 33 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01189266 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | completed | Phase 1 / Phase 2 | 79 | National Cancer Institute (NCI)NIH | 3 | Oct 28, 2021 | clinicaltrials |
| NCT02015819 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01156584 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | completed | Phase 1 | 54 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01470794 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | completed | Phase 1 | 58 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | completed | Phase 1 | 17 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01172964 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT01250470 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01144247 | Cellular Immunotherapy Study for Brain Cancer(alloCTL) | completed | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT00884416 | Sorafenib in Newly Diagnosed High Grade Glioma | completed | Phase 1 | 17 | University Hospital, GenevaOTHER | 1 | Nov 4, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 16, 2025source: clinicaltrials